ATE493413T1 - Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3- - Google Patents

Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-

Info

Publication number: ATE493413T1
Authority: AT; Austria
Prior art keywords: ethoxyethyl; ethyl; crystalline forms; anhydrous crystalline; methylaminoü
Prior art date: 2005-05-12

Application number

AT06744689T

Other languages

English (en)

Inventor

David Andrew Entwistle

Peter Vallance Marshall

Stefan Colin John Taylor

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-12

Filing date

2006-05-03

Publication date

2011-01-15

2006-05-03 Application filed by Pfizer filed Critical Pfizer

2011-01-15 Application granted granted Critical

2011-01-15 Publication of ATE493413T1 publication Critical patent/ATE493413T1/de

Links

ZUHZNKJIJDAJFD-UHFFFAOYSA-N 1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]-n-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide Chemical compound C=12N(CCOCC)N=C(C(=O)NS(C)(=O)=O)C2=NC(N(C)CC)=NC=1NC1=CC(C)=CC=N1 ZUHZNKJIJDAJFD-UHFFFAOYSA-N 0.000 abstract 2
102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pregnancy & Childbirth (AREA)

AT06744689T 2005-05-12 2006-05-03 Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3- ATE493413T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US68044505P	2005-05-12	2005-05-12
US68171105P	2005-05-17	2005-05-17
PCT/IB2006/001233 WO2006120552A2 (en)	2005-05-12	2006-05-03	ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE

Publications (1)

Publication Number	Publication Date
ATE493413T1 true ATE493413T1 (de)	2011-01-15

Family

ID=37106941

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06744689T ATE493413T1 (de)	2005-05-12	2006-05-03	Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-

Country Status (23)

Country	Link
US (3)	US8227475B2 (de)
EP (1)	EP1881985B1 (de)
JP (2)	JP4271695B2 (de)
KR (1)	KR100939890B1 (de)
AT (1)	ATE493413T1 (de)
AU (1)	AU2006245416B2 (de)
BR (1)	BRPI0609225A2 (de)
CA (1)	CA2608018C (de)
CR (1)	CR9505A (de)
CY (1)	CY1111171T1 (de)
DE (1)	DE602006019231D1 (de)
DK (1)	DK1881985T3 (de)
EA (1)	EA012577B1 (de)
IL (1)	IL186693A (de)
MA (1)	MA29447B1 (de)
MX (1)	MX2007013215A (de)
NO (1)	NO20075258L (de)
NZ (1)	NZ564187A (de)
PL (1)	PL1881985T3 (de)
PT (1)	PT1881985E (de)
TN (1)	TNSN07414A1 (de)
TW (1)	TWI380986B (de)
WO (1)	WO2006120552A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7676953B2 (en) *	2006-12-29	2010-03-16	Signature Control Systems, Inc.	Calibration and metering methods for wood kiln moisture measurement
WO2009050554A2 (en) *	2007-10-19	2009-04-23	Pfizer Inc.	Treatment of central nervous system disorders
WO2012048330A2 (en) *	2010-10-08	2012-04-12	The Mclean Hospital Corporation	Treatment of motor neuron disease
WO2012131539A1 (en)	2011-03-31	2012-10-04	Pfizer Inc.	Novel bicyclic pyridinones
AU2012244550C1 (en)	2011-04-21	2017-06-22	Origenis Gmbh	Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
WO2012172449A1 (en)	2011-06-13	2012-12-20	Pfizer Inc.	Lactams as beta secretase inhibitors
CN102952138B (zh) *	2011-08-17	2016-07-06	上海特化医药科技有限公司	一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
JP6043355B2 (ja)	2011-08-31	2016-12-14	ファイザー・インク	ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
ES2585262T3 (es)	2012-05-04	2016-10-04	Pfizer Inc	Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
CA2882389A1 (en)	2012-09-20	2014-03-27	Pfizer Inc.	Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
US9637491B2 (en)	2012-10-19	2017-05-02	Origenis Gmbh	Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
CN104755086A (zh)	2012-10-23	2015-07-01	辉瑞公司	四取代的吡唑并[4,3-d]嘧啶化合物用于治疗糖尿病肾病的用途
WO2014091352A1 (en)	2012-12-11	2014-06-19	Pfizer Inc.	Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2893333C (en)	2012-12-19	2017-10-24	Pfizer Inc.	Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014125394A1 (en)	2013-02-13	2014-08-21	Pfizer Inc.	HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
AP2015008663A0 (en)	2013-02-19	2015-08-31	Pfizer	Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders
CA2925743C (en)	2013-10-04	2018-03-06	Pfizer Inc.	Novel bicyclic pyridinones as gamma-secretase modulators
PE20161364A1 (es)	2014-04-01	2016-12-25	Pfizer	CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
CR20160455A (es)	2014-04-10	2016-12-16	Pfizer	2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILA
EP3172210B1 (de)	2014-07-24	2020-01-15	Pfizer Inc	Pyrazolopyrimidin verbindungen
SG11201700243YA (en)	2014-08-06	2017-02-27	Pfizer	Imidazopyridazine compounds
TN2017000342A1 (en)	2015-02-03	2019-01-16	Pfizer	Novel cyclopropabenzofuranyl pyridopyrazinediones
ES2832893T3 (es)	2015-06-17	2021-06-11	Pfizer	Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
JP2018531924A (ja)	2015-09-24	2018-11-01	ファイザー・インク	テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
EP3353174A1 (de)	2015-09-24	2018-08-01	Pfizer Inc	N-[2-(3-amino-2,5-dimethyl-1,1-dioxid-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)]-1,3-thiazol-4-yl-amide als bace-hemmer
WO2017051276A1 (en)	2015-09-24	2017-03-30	Pfizer Inc.	N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
PL3419979T3 (pl)	2016-02-23	2020-06-29	Pfizer Inc.	Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe
HUE054857T2 (hu)	2016-07-01	2021-10-28	Pfizer	5,7-dihidro-pirrolo-piridinszármazékok neurológiai és neurodegeneratív betegségek kezelésére
CN110944998B (zh)	2017-06-22	2022-08-16	辉瑞大药厂	二氢-吡咯并-吡啶衍生物
ES2942837T3 (es)	2018-03-23	2023-06-07	Pfizer	Derivados de azaespiro piperazina
WO2022182658A1 (en)	2021-02-23	2022-09-01	Hoth Therapeutics, Inc.	Use of aprepitant for treating alzheimer's disease
WO2024118524A1 (en)	2022-11-28	2024-06-06	Cerevel Therapeutics, Llc	Azaindole compounds and their use as phosphodiesterase inhibitors
WO2025145091A1 (en)	2023-12-29	2025-07-03	Pfizer Inc.	Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9119704D0 (en)	1991-09-14	1991-10-30	Pfizer Ltd	Therapeutic agents
GB9121028D0 (en)	1991-10-03	1991-11-13	Pfizer Ltd	Therapeutic agents
GB9126260D0 (en)	1991-12-11	1992-02-12	Pfizer Ltd	Therapeutic agents
GB9213623D0 (en)	1992-06-26	1992-08-12	Pfizer Ltd	Therapeutic agents
GB9218322D0 (en)	1992-08-28	1992-10-14	Pfizer Ltd	Therapeutic agents
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
SK285991B6 (sk)	1997-04-25	2008-01-07	Pfizer Inc.	Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze
TR200001338T2 (tr)	1997-11-12	2000-08-21	Bayer Aktiengesellschaft	2-Fenil-ikameli imidazotriazinonlar
EP1371647B1 (de)	1998-04-20	2005-07-13	Pfizer Inc.	Pyridin-3-carbonsäurederivate und ihre Verwendung als Zwischenprodukte
DE69911448T2 (de)	1998-10-23	2004-04-08	Pfizer Inc.	Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
DE19942474A1 (de)	1999-09-06	2001-03-15	Merck Patent Gmbh	Pyrazolo[4,3-d]pyrimidine
EP1222190A1 (de)	1999-10-11	2002-07-17	Pfizer Limited	2-(2-substituted-5-heterocyclylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-one als phosphodiesterasehemmer
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
DE10031584A1 (de)	2000-06-29	2002-01-10	Merck Patent Gmbh	5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
EP1305314B1 (de)	2000-07-28	2005-01-12	Pfizer Limited	Kristallin-therapeutisches mittel
ATE478872T1 (de) *	2002-03-28	2010-09-15	Ustav Ex Botan Av Cr V V I I O	Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
EA008596B1 (ru)	2003-04-29	2007-06-29	Пфайзер Инк.	5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
GB0327319D0 (en)	2003-11-24	2003-12-24	Pfizer Ltd	Novel pharmaceuticals
US7572799B2 (en) *	2003-11-24	2009-08-11	Pfizer Inc	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327323D0 (en)	2003-11-24	2003-12-31	Pfizer Ltd	Novel pharmaceuticals
DK1742950T3 (da)	2004-04-07	2009-03-16	Pfizer Ltd	Pyrazolo-[4,3-D]-pyrimidiner
JP2008517994A (ja)	2004-10-28	2008-05-29	ファルマシア・アンド・アップジョン・カンパニー・エルエルシー	新規医薬品

2006
- 2006-05-03 CA CA2608018A patent/CA2608018C/en not_active Expired - Fee Related
- 2006-05-03 DE DE602006019231T patent/DE602006019231D1/de not_active Expired - Lifetime
- 2006-05-03 US US11/913,091 patent/US8227475B2/en not_active Expired - Fee Related
- 2006-05-03 EA EA200702217A patent/EA012577B1/ru not_active IP Right Cessation
- 2006-05-03 AU AU2006245416A patent/AU2006245416B2/en not_active Ceased
- 2006-05-03 EP EP06744689A patent/EP1881985B1/de not_active Expired - Lifetime
- 2006-05-03 PL PL06744689T patent/PL1881985T3/pl unknown
- 2006-05-03 DK DK06744689.8T patent/DK1881985T3/da active
- 2006-05-03 BR BRPI0609225-0A patent/BRPI0609225A2/pt not_active IP Right Cessation
- 2006-05-03 WO PCT/IB2006/001233 patent/WO2006120552A2/en not_active Ceased
- 2006-05-03 NZ NZ564187A patent/NZ564187A/en not_active IP Right Cessation
- 2006-05-03 MX MX2007013215A patent/MX2007013215A/es active IP Right Grant
- 2006-05-03 AT AT06744689T patent/ATE493413T1/de active
- 2006-05-03 KR KR1020077026098A patent/KR100939890B1/ko not_active Expired - Fee Related
- 2006-05-03 PT PT06744689T patent/PT1881985E/pt unknown
- 2006-05-11 TW TW095116704A patent/TWI380986B/zh not_active IP Right Cessation
- 2006-05-11 JP JP2006132110A patent/JP4271695B2/ja not_active Expired - Fee Related
2007
- 2007-10-12 NO NO20075258A patent/NO20075258L/no not_active Application Discontinuation
- 2007-10-16 IL IL186693A patent/IL186693A/en not_active IP Right Cessation
- 2007-11-09 CR CR9505A patent/CR9505A/es unknown
- 2007-11-09 TN TNP2007000414A patent/TNSN07414A1/fr unknown
- 2007-11-12 MA MA30362A patent/MA29447B1/fr unknown
2009
- 2009-01-07 JP JP2009001627A patent/JP4996631B2/ja not_active Expired - Fee Related
2011
- 2011-02-08 CY CY20111100142T patent/CY1111171T1/el unknown
2012
- 2012-04-27 US US13/457,886 patent/US8796287B2/en not_active Expired - Fee Related
- 2012-04-27 US US13/457,969 patent/US8796288B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2006245416A1 (en)	2006-11-16
US8227475B2 (en)	2012-07-24
US20080194591A1 (en)	2008-08-14
EP1881985A2 (de)	2008-01-30
MA29447B1 (fr)	2008-05-02
EA200702217A1 (ru)	2008-04-28
NZ564187A (en)	2010-03-26
JP4271695B2 (ja)	2009-06-03
EA012577B1 (ru)	2009-10-30
PT1881985E (pt)	2011-02-01
US8796287B2 (en)	2014-08-05
MX2007013215A (es)	2007-12-12
CY1111171T1 (el)	2015-06-11
JP4996631B2 (ja)	2012-08-08
PL1881985T3 (pl)	2011-05-31
US20120214827A1 (en)	2012-08-23
TWI380986B (zh)	2013-01-01
HK1116485A1 (en)	2008-12-24
IL186693A (en)	2012-07-31
AU2006245416B2 (en)	2012-02-23
JP2006316058A (ja)	2006-11-24
US20120208830A1 (en)	2012-08-16
TW200716641A (en)	2007-05-01
WO2006120552A2 (en)	2006-11-16
CA2608018A1 (en)	2006-11-16
KR20080004593A (ko)	2008-01-09
WO2006120552A3 (en)	2007-01-18
CR9505A (es)	2008-01-02
CA2608018C (en)	2010-07-13
BRPI0609225A2 (pt)	2010-03-09
JP2009137987A (ja)	2009-06-25
NO20075258L (no)	2007-11-15
DK1881985T3 (da)	2011-02-14
EP1881985B1 (de)	2010-12-29
KR100939890B1 (ko)	2010-01-29
IL186693A0 (en)	2008-02-09
US8796288B2 (en)	2014-08-05
TNSN07414A1 (fr)	2009-03-17
DE602006019231D1 (en)	2011-02-10

Legal Events

Date

Code

Title

Description

2011-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1881985

Country of ref document: EP

Publication	Publication Date	Title
EA200702217A1 (ru)	2008-04-28	Безводные кристаллические формы n-[1-(2-этоксиэтил)-5-(n-этил-n-метиламино)-7-(4-метилпиридин-2-иламино)-1h-пиразоло[4,3-d]пиримидин-3-карбонил]метансульфонамида
ATE430747T1 (de)	2009-05-15	2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
WO2007067506A3 (en)	2007-08-16	2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
NO20071915L (no)	2007-05-18	Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
NO20071077L (no)	2007-04-26	Fosfonatanaloger til HIV-inhibitorforbindelser
MXPA05012025A (es)	2006-02-03	Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
NO20053470L (no)	2005-09-02	Triazolopyridaziner som proteinkinase-inhibitorer
EA200701802A1 (ru)	2008-02-28	Имидазо(1,2-а)пиридиновые соединения в качестве ингибиторов vegf-r2
WO2003095455A3 (en)	2003-12-24	Substituted pyrazolopyrimidines
WO2007041130A3 (en)	2010-01-21	Deazapurines useful as inhibitors of janus kinases
WO2004074244A3 (en)	2004-11-11	Pyrimidine compounds
PT1379520E (pt)	2006-08-31	Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b
NO20074431L (no)	2007-08-31	Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
ZA200710379B (en)	2009-05-27	Pyrrolopyridines useful as inhibitors of protein kinase
TW200604168A (en)	2006-02-01	Azaindoles useful as inhibitors of rock and other protein kinases
WO2007084424A3 (en)	2007-10-04	Treatment of substance abuse
NO20075099L (no)	2007-10-29	Alkynyl-pyrrolopyrmidiner og relaterte analoger som HSP90-inhibitorer
TW200510407A (en)	2005-03-16	Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
MY140514A (en)	2009-12-31	Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2006116148A3 (en)	2008-09-12	(7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
WO2007084557A3 (en)	2007-09-27	Azaindoles useful as inhibitors of janus kinases
WO2007068934A3 (en)	2008-02-21	Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
WO2005032490A3 (en)	2005-07-28	Cyclic diamines and derivatives as factor xa inhibitors
WO2007120333A3 (en)	2008-01-10	Tetracyclic kinase inhibitors
WO2004072029A3 (en)	2004-12-16	Pyrazolopyridazines useful as inhibitors of protein kinases